Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OLANI
- Development stage
- Phase 2
- Lead developer
- GoMedical
- Modality
- Small Molecules, Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Subcutaneous Implant
01
Overview
OLANI is a biodegradable, long-acting **naltrexone implant** developed to provide extended treatment for opioid use disorder. Implanted subcutaneously in the abdomen via a minor surgical procedure, it gradually dissolves and releases naltrexone over a 6-month period, aiming to improve medication adherence and reduce relapse rates in opioid-dependent patients. This product is a novel formulation of naltrexone distinguished from existing monthly injectable products by its extended duration of pharmacological action and biodegradable matrix.[1]
- Brand names
- OLANI
- Other names
- O’Neil Long Acting Naltrexone Implant
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on OLANI.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OLANI.